Wall Street brokerages expect DENTSPLY SIRONA Inc (NASDAQ:XRAY) to report sales of $1.08 billion for the current quarter, Zacks reports. Seven analysts have provided estimates for DENTSPLY SIRONA’s earnings, with estimates ranging from $1.07 billion to $1.10 billion. DENTSPLY SIRONA posted sales of $1.06 billion in the same quarter last year, which would indicate a positive year-over-year growth rate of 1.9%. The firm is scheduled to issue its next quarterly earnings results on Friday, March 6th.
On average, analysts expect that DENTSPLY SIRONA will report full-year sales of $3.99 billion for the current year, with estimates ranging from $3.96 billion to $4.02 billion. For the next financial year, analysts expect that the company will post sales of $4.11 billion, with estimates ranging from $4.07 billion to $4.13 billion. Zacks’ sales averages are an average based on a survey of research firms that cover DENTSPLY SIRONA.
DENTSPLY SIRONA (NASDAQ:XRAY) last released its quarterly earnings results on Thursday, November 7th. The medical instruments supplier reported $0.57 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.50 by $0.07. The company had revenue of $962.10 million during the quarter, compared to analysts’ expectations of $940.38 million. DENTSPLY SIRONA had a return on equity of 10.08% and a net margin of 4.08%. The company’s revenue for the quarter was up 3.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.38 earnings per share.
A number of equities analysts recently issued reports on XRAY shares. ValuEngine lowered shares of DENTSPLY SIRONA from a “hold” rating to a “sell” rating in a research report on Wednesday, October 2nd. BidaskClub upgraded shares of DENTSPLY SIRONA from a “hold” rating to a “buy” rating in a research report on Friday. Finally, HC Wainwright reaffirmed a “hold” rating and issued a $60.00 price target on shares of DENTSPLY SIRONA in a research note on Friday, November 15th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and four have issued a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $56.08.
Shares of NASDAQ XRAY traded down $0.24 during midday trading on Thursday, reaching $58.05. 1,186,656 shares of the company traded hands, compared to its average volume of 1,432,416. The company has a market cap of $12.96 billion, a price-to-earnings ratio of 28.88, a PEG ratio of 2.04 and a beta of 0.95. The stock has a 50-day moving average price of $56.00 and a 200 day moving average price of $54.74. DENTSPLY SIRONA has a 52 week low of $34.93 and a 52 week high of $60.15. The company has a debt-to-equity ratio of 0.30, a current ratio of 2.08 and a quick ratio of 1.39.
In other news, Director Michael C. Alfano sold 10,665 shares of the company’s stock in a transaction on Tuesday, November 12th. The stock was sold at an average price of $56.27, for a total value of $600,119.55. Following the completion of the sale, the director now owns 15,153 shares in the company, valued at $852,659.31. The sale was disclosed in a legal filing with the SEC, which is available at this link. 0.62% of the stock is currently owned by insiders.
Hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. lifted its holdings in DENTSPLY SIRONA by 7.0% in the 2nd quarter. Vanguard Group Inc. now owns 25,969,056 shares of the medical instruments supplier’s stock valued at $1,515,556,000 after acquiring an additional 1,688,546 shares during the last quarter. BlackRock Inc. boosted its holdings in DENTSPLY SIRONA by 3.2% during the second quarter. BlackRock Inc. now owns 14,735,875 shares of the medical instruments supplier’s stock worth $859,985,000 after buying an additional 458,934 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in DENTSPLY SIRONA by 1.6% during the second quarter. Price T Rowe Associates Inc. MD now owns 5,471,623 shares of the medical instruments supplier’s stock worth $319,324,000 after buying an additional 87,294 shares in the last quarter. Atlanta Capital Management Co. L L C grew its position in DENTSPLY SIRONA by 0.8% in the second quarter. Atlanta Capital Management Co. L L C now owns 4,673,039 shares of the medical instruments supplier’s stock worth $272,719,000 after buying an additional 39,156 shares during the last quarter. Finally, Northern Trust Corp grew its position in DENTSPLY SIRONA by 12.2% in the second quarter. Northern Trust Corp now owns 2,919,933 shares of the medical instruments supplier’s stock worth $170,407,000 after buying an additional 317,282 shares during the last quarter. 94.35% of the stock is owned by institutional investors and hedge funds.
DENTSPLY SIRONA Company Profile
DENTSPLY SIRONA Inc designs, develops, manufactures, and markets various dental and oral health products, and other consumable healthcare products primarily for the professional dental market worldwide. The company operates in two segments, Technologies & Equipment; and Consumables. Its dental supplies include endodontic instruments and materials, dental anesthetics, prophylaxis pastes, dental sealants, impression materials, restorative materials, tooth whiteners, and topical fluoride products; and small equipment products comprise dental hand pieces, intraoral curing light systems, dental diagnostic systems, and ultrasonic scalers and polishers.
Further Reading: 52 Week Highs and Lows
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for DENTSPLY SIRONA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA and related companies with MarketBeat.com's FREE daily email newsletter.